Boehringer Ingelheim deepens its collaboration with Click Therapeutics in a deal worth $460M
Boehringer Ingelheim inked a massive collaboration with digital therapeutics company Click Therapeutics two years ago — and now its expanding.
On Monday, the German pharma announced the launch of an “expanded collaboration” between Boehringer Ingelheim and Click to develop and commercialize a second “prescription-based digital therapeutic.” The collaboration will center on schizophrenia and aim to combine multiple therapeutic interventions for use with pharmaceutical therapy to help people with the disease.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.